Gorbatchev D, Ramírez-Venegas A, Mayar-Maya ME, Sansores RH, Guzmán-Barragán A, Regalado J

Language: Spanish
References: 16
Page: 102-107
PDF size: 126.55 Kb.

ABSTRACT

Background: Tobacco smoking is one of the major modifiable cardiovascular risk factors. The relationship between smoking and lipid disorders has been studied; however, its prevalence among smokers from our Smoking Cessation Clinic (SCC) “Dra. Carmen Gutiérrez de Velasco” at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas is unknown.
Objective: To describe the lipid profile of smokers at our SCC and its prevalence in this population.
Methods: 700 medical records from patients admitted to the clinic during a three- year period from 2003 to 2005 were studied. We analyzed the prevalence of their atherogenic lipid profile defined as high serum total cholesterol and triglycerides and low HDL-cholesterol. In addition, we studied the prevalence of each component of the lipid profile, according to a gender and a number of cigarettes (cig) smoked per day.
Results: The prevalence of atherogenic lipid profile, hypercholesterolemia, hypertriglyceridemia and low HDL-cholesterol was 21%, 50% 56% and 55%, respectively. Their total serum cholesterol and triglycerides levels were high and HDL-cholesterol was low (CT 204 ± 44 mg/dL, TG 208 ± 155 mg/dL, HDL 46 ± 14 mg/dL). Those who smoked more than 20 cig/day had higher triglycerides and lower HDL-cholesterol than those smoking less than 20 cig/day (225 ± 162 mg/dL vs 185 ± 134 mg/dL, p = 0.02 and 44.2 ± 12 mg/dL vs 48 ± 14 mg/dL, p‹0.001, respectively). Women had higher HDLcholesterol than men (51 ± 14 mg/dL vs 40.3 ± 11 mg/dL, p ‹ 0.001).
Conclusion: The high prevalence of an atherogenic lipid profile in smokers makes them prone to develop premature atherosclerosis. This study underscores the importance of lipid disorders research in smokers.

REFERENCES

1. World Health Organization. World Health Statistics Annual: 1996. Ginebra, 1998.

2. US. Department of Health and Human Services. The Health Benefits of Smoking Cessation. A Report of the Surgeon General. USDHHS, Centers for Disease Control. Office of Smoking and Health; 1990. DHHS Publication (CDC) 90-8416.

3. Ross R. Mechanisms of disease: Atherosclerosis -an inflammatory disease. N Engl J Med 1999;340:115-126.

4. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking-cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239.

5. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.

6. Sansores RH, Espinosa AM. Programa cognitivoconductual de la Clínica para Dejar de Fumar. México, DF: INER;1999.

7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-3421.

8. Whig J, Singh CB, Soni GL, Bansal AK. Serum lipids and lipoprotein profiles of cigarette smokers and passive smokers. Indian J Med Res 1992;96:282-287.

9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.

10. 10.Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005;149:832-839.

11. 11.Olsson AG, Schwartz GG,Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influences short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890-896.

12. 12.Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol 2002;90:77i-84i.

13. 13.Marín F, Prada M. Relación del tabaquismo como factor de riesgo para el tipo de evento coronario agudo (IAM vs angina inestable) en 1,592 pacientes. Rev Colomb Cardiol 2003;10:391-399.

14. 14.Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis 1988;74:85-89.

15. 15.Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994;309: 901-911.

16. 16.Sansores-Martínez RH, Córdoba-Ponce MP, Espinosa-Martínez M, et al. Evaluación del programa cognitivo-conductual para dejar de fumar del Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp Mex 1998;11:29-35.